A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 420 participants.

Also called NCT07642050

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Biohaven Therapeutics Ltd. (from the registry)
Registry
  • NCT NCT07642050
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07642050. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2028-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
Condition
IgA Nephropathy
Intervention (Drug)
BHV-1400
Intervention (Drug)
Placebo
Lead sponsor
Biohaven Therapeutics Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07642050
Content hash
187f55e9e2af023f88b585ca317b8ffc4cdea7f3d52f2caa40fa291fd5c7c545